These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 33934692

  • 1. Efficacy of GLP-1rA, liraglutide, in plaque psoriasis treatment with type 2 diabetes: a systematic review and meta-analysis of prospective cohort and before-after studies.
    Chang G, Chen B, Zhang L.
    J Dermatolog Treat; 2022 May; 33(3):1299-1305. PubMed ID: 33934692
    [Abstract] [Full Text] [Related]

  • 2. Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.
    Faurschou A, Gyldenløve M, Rohde U, Thyssen JP, Zachariae C, Skov L, Knop FK, Vilsbøll T.
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):555-9. PubMed ID: 25139195
    [Abstract] [Full Text] [Related]

  • 3. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials.
    Vilsbøll T, Christensen M, Junker AE, Knop FK, Gluud LL.
    BMJ; 2012 Jan 10; 344():d7771. PubMed ID: 22236411
    [Abstract] [Full Text] [Related]

  • 4. Treatment with liraglutide, a glucagon-like peptide-1 analogue, improves effectively the skin lesions of psoriasis patients with type 2 diabetes: A prospective cohort study.
    Xu X, Lin L, Chen P, Yu Y, Chen S, Chen X, Shao Z.
    Diabetes Res Clin Pract; 2019 Apr 10; 150():167-173. PubMed ID: 30844468
    [Abstract] [Full Text] [Related]

  • 5. Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
    Ahern T, Tobin AM, Corrigan M, Hogan A, Sweeney C, Kirby B, O'Shea D.
    J Eur Acad Dermatol Venereol; 2013 Nov 10; 27(11):1440-3. PubMed ID: 22691169
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of Glucagon-Like Peptide 1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Network Meta-analysis.
    Jiang Y, Liu J, Chen X, Yang W, Jia W, Wu J.
    Adv Ther; 2021 Mar 10; 38(3):1470-1482. PubMed ID: 33582976
    [Abstract] [Full Text] [Related]

  • 7. Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.
    Siskind D, Hahn M, Correll CU, Fink-Jensen A, Russell AW, Bak N, Broberg BV, Larsen J, Ishøy PL, Vilsbøll T, Knop FK, Kisely S, Ebdrup BH.
    Diabetes Obes Metab; 2019 Feb 10; 21(2):293-302. PubMed ID: 30187620
    [Abstract] [Full Text] [Related]

  • 8. Glucagon-like peptide-1 receptor agonist liraglutide therapy for psoriasis patients with type 2 diabetes: a randomized-controlled trial.
    Lin L, Xu X, Yu Y, Ye H, He X, Chen S, Chen X, Shao Z, Chen P.
    J Dermatolog Treat; 2022 May 10; 33(3):1428-1434. PubMed ID: 32962477
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Glucagon-like peptide-1 receptor agonists and risk of bone fracture in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Cheng L, Hu Y, Li YY, Cao X, Bai N, Lu TT, Li GQ, Li N, Wang AN, Mao XM.
    Diabetes Metab Res Rev; 2019 Oct 10; 35(7):e3168. PubMed ID: 30974033
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population.
    Nguyen H, Dufour R, Caldwell-Tarr A.
    Adv Ther; 2017 Mar 10; 34(3):658-673. PubMed ID: 28078541
    [Abstract] [Full Text] [Related]

  • 14. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ.
    Circulation; 2017 Aug 29; 136(9):849-870. PubMed ID: 28847797
    [Abstract] [Full Text] [Related]

  • 15. Effects of treatment with Glucagon-like peptide-1 receptor agonist on prediabetes with overweight/obesity: A systematic review and meta-analysis.
    Wang W, Wei R, Huang Z, Luo J, Pan Q, Guo L.
    Diabetes Metab Res Rev; 2023 Oct 29; 39(7):e3680. PubMed ID: 37356073
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis.
    Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Ji L, Zhan S.
    Endocrine; 2015 Apr 29; 48(3):794-803. PubMed ID: 25115635
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V.
    J Am Heart Assoc; 2020 May 05; 9(9):e015716. PubMed ID: 32326806
    [Abstract] [Full Text] [Related]

  • 20. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis.
    Sun F, Wu S, Guo S, Yu K, Yang Z, Li L, Zhang Y, Quan X, Ji L, Zhan S.
    Diabetes Res Clin Pract; 2015 Oct 05; 110(1):26-37. PubMed ID: 26358202
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.